Mohammad Shahrokh Esfahani
Also known as: Mohammad S Esfahani
Stanford University, Texas A&M University, Sharif University of Technology
Research areas: Medicine · Pathology and Forensic Medicine · Cancer Genomics and Diagnostics · Lymphoma Diagnosis and Treatment · Lung Cancer Diagnosis and Treatment
0000-0002-0950-3937
About
I am a Biomedical Data Scientist interested in cancer genomics, computational oncology and liquid biopsies. After receiving my PhD in Electrical Engineering from Texas A&M University in 2014, I spent seven months working on a project sponsored by Los Alamos National Lab. I joined Stanford Medicine in 2015 as a postdoctoral researcher in Alizadeh and Diehn labs. I have worked on various problems concerning liquid biopsy and more in the past seven years. I received both BS and MS in Electrical Engineering from the University of Tehran and Sharif University of Technology (Iran), in 2007 and 2009, respectively.
Employment
-
Stanford University Assistant Professor2024 - Present
-
Stanford University Instructor2020 - 2024
-
Stanford University Postdoctoral Fellow2015 - 2020
Education
-
Texas A&M University Doctor of Philosophy (PhD)2009 - 2014
-
Sharif University of Technology Master of Science2007 - 2009
Projects & Funding
Projects & funding information is unavailable.
Publications (73)
- Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes. Save
- Field-effect-informed urine liquid biopsy for bladder cancer. Save
- Loss of payload sensitivity and other mechanisms of resistance to T-DXd in HER2-mutant NSCLC: implications for subsequent responsiveness to HER2 TKIs. Save
- Data from Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer Save
- Figures S1-S8 from Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer Save
- Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer Save
- Table S1-S10 from Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer Save
- Direct Method for Estimating the Fraction of T and B/Plasma Cell-Derived DNA Save
- Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas Save
- Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma Save
- Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling Save
- Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification Save
- Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas Save
- Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas. Save
- Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer. Save
- Inferring gene expression from cell-free DNA fragmentation profiles Save
- Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA Save
- Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing Save
- Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma Save
- The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma Save